Company: TXG
Filing Date: 2025-05-14
Form Type: 8-K
Source: 0001770787-25-000035
Chunk: 0

Company: 10x Genomics, Inc.
Filing Date: 2025-05-14
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

On May 12, 2025, 10x Genomics, Inc. (the “ Company”) entered into a settlement agreement and license agreements (the “ Agreements”) with Bruker Corporation (“ Bruker”) resolving all outstanding litigation and other proceedings between the parties across all jurisdictions around the world. The Company anticipates the parties will dismiss all claims with prejudice in all jurisdictions including actions pending in the United States, in Germany and before the European Unified Patent Court, within five days of May 12, 2025.

The Company had originally filed suit on May 6, 2021, against NanoString Technologies, Inc. (“ NanoString”) in the U. S. District Court for the District of Delaware. The suit alleged that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U. S. Patent Nos. 10,472,669, 10,961,566, 10,983,113, 10,996,219, 11,001,878, 11,008,607 and 11,293,917.

On February 28, 2022, the Company filed a second suit against NanoString in the U. S. District Court for the District of Delaware. The suit alleged that NanoString’s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U. S. Patent Nos. 10,227,639, 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,542,554.

In May 2024, Bruker acquired certain assets and assumed certain liabilities of NanoString, including the litigation between the Company and NanoString, and the NanoString product lines subject to the lawsuits.

Pursuant to the terms of the Agreements the Company expects to receive up-front nonrefundable payments totaling $68 million, paid in equal quarterly installments with interest, between the third quarter of 2025 and the second quarter of 2026, as well as ongoing royalty payments related to the licensed products and services through the life of the licensed patents.

Forward-looking Statements

This Current Report on Form 8-K (this “ Current Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of